Physician profile
Cara E Pittari
NPI 1548493273
$10,005.74
in general payments reported to CMS, 2019-2025
50 companies · $1,996 in 2025
The $1,996 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $200 · 2021: $744 · 2022: $1,544 · 2023: $2,084 · 2024: $2,735 · 2025: $1,996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,815.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,186.25 | 2021-2025 | |
| Emd Serono, INC. | $779.11 | 2019-2025 | Mavenclad |
| Ucb, INC. | $552.85 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Amgen INC. | $521.10 | 2019-2025 | Uplizna, Aimovig |
| Genentech USA, INC. | $492.88 | 2021-2025 | Ocrevus Zunovo, Ocrevus |
| Lundbeck LLC | $467.91 | 2022-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $467.44 | 2022-2025 | |
| Argenx US, INC. | $385.30 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $372.66 | 2022-2025 | Kisunla, Amyvid, Jardiance |
| Biogen, INC. | $346.88 | 2019-2024 | Vumerity, Tysabri |
| Neurocrine Biosciences, INC. | $343.78 | 2020-2024 | Ingrezza, Ongentys |
| Allergan, INC. | $309.17 | 2019-2020 | |
| Eisai INC. | $272.34 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $261.94 | 2023-2025 | Rexulti, Nuedexta |
| Alexion Pharmaceuticals, INC. | $250.76 | 2023-2025 | Ultomiris |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $247.01 | 2022-2025 | |
| Pfizer INC. | $187.61 | 2023-2025 | |
| Livanova USA, INC. | $177.87 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $156.09 | 2021-2023 | Austedo Xr, Austedo |
| Sk Life Science, INC. | $152.85 | 2022-2024 | Xcopri |
| Amneal Pharmaceuticals LLC | $145.58 | 2022-2024 | Rytary |
| Biohaven Pharmaceutical Holding Company LTD. | $143.77 | 2022 | |
| Neurelis, INC. | $143.55 | 2021-2025 | Valtoco |
| Janssen Pharmaceuticals, INC | $140.62 | 2021-2023 | Ponvory |
| Avanir Pharmaceuticals, INC. | $134.76 | 2022 | |
| Tg Therapeutics, INC. | $114.03 | 2023-2025 | |
| Upsher-Smith Laboratories LLC | $112.39 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $106.82 | 2019-2025 | Qelbree |
| Kyowa Kirin, INC. | $104.03 | 2019-2023 | Nourianz |
| Celgene Corporation | $99.33 | 2021-2023 | Zeposia |
| Horizon Therapeutics Plc | $98.90 | 2023 | Uplizna |
| Biohaven Pharmaceuticals, INC. | $90.78 | 2021 | |
| Axsome Therapeutics, INC. | $80.08 | 2024-2025 | Auvelity, Symbravo |
| Astrazeneca Pharmaceuticals LP | $66.42 | 2021-2024 | Farxiga |
| Penumbra, INC. | $52.99 | 2023 | Penumbra System |
| Sunovion Pharmaceuticals INC. | $47.29 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $43.11 | 2022-2023 | Nuplazid |
| Scilex Pharmaceuticals INC. | $42.40 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.87 | 2022 | |
| Mdd US Operations, LLC | $38.68 | 2023-2024 | Gocovri, Gocovri |
| Avion Pharmaceuticals | $32.37 | 2022 | |
| Insightec,INC | $31.74 | 2025 | Exablate |
| Neuropace, INC. | $24.68 | 2022 | |
| Csl Behring | $24.58 | 2025 | Hizentra |
| Grifols USA, LLC | $24.14 | 2023 | Gamunex-C |
| Jazz Pharmaceuticals INC. | $22.91 | 2022 | |
| Circassia INC. | $20.78 | 2019 | |
| Novo Nordisk INC | $18.75 | 2023 | |
| Promius Pharma LLC | $15.36 | 2019 | |
| Amarin Pharma, INC. | $14.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Pittari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.